Triomics Secures $22M Series B After $15M Series A
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Triomics builds an AI‑powered platform to automate data‑heavy tasks for oncologists.
- Triomics raised $22M in a Series B, after a $15M Series A in 2024.
Why it matters: Oncologists gain faster, automated data handling, while investors see a $37 million capital boost, accelerating AI deployment in oncology and cutting administrative costs in cancer treatment.
